Following the publication of a landmark paper on comparative effectiveness of anticoagulation against thrombolysis, the authors of the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial released a subanalysis targeting the iliofemoral vein thrombosis, which excluded the femoropopliteal deep vein thrombosis (DVT) population. Similar to the primary publication, the ATTRACT-iliofemoral results again challenge the utility of pharmacomechanical thrombolysis (PMT) and catheter-directed thrombolysis (CDT) in preventing post-thrombotic syndrome (PTS) ( , ). Their analysis reported no difference in the development of PTS (defined as Villalta score ≥5) between patients with proximal DVT treated with PMT/CDT and anticoagulation alone [relative risk (RR), 0.95; 95% confidence interval (CI), 0.78–1.15; P=0.59] at 24 months after treatment. This result contradicts that of their Norwegian contemporaries of the 2012 Catheter-directed Venous Thrombolysis (CaVenT) trial—a smaller randomized control trial which reported a lower rate of PTS in patients treated with CDT over anticoagulation alone ( ).
展开▼
机译：在发表有关抗凝抗溶栓的相对有效性的里程碑式论文发表之后，“急性静脉血栓形成：辅助导管导向溶栓的血栓清除术”（ATTRACT）试验的作者发布了针对股静脉血栓形成的亚分析，其中排除了股pop深静脉血栓形成（DVT）人群。与主要出版物相似，ATTRACT ili股的结果再次挑战了药物机械溶栓（PMT）和导管定向溶栓（CDT）在预防血栓形成后综合征（PTS）中的实用性（）。他们的分析报告说，接受PMT / CDT治疗的近端DVT患者和单独抗凝治疗的患者，PTS的发展（定义为Villalta评分≥5）没有差异[相对危险度（RR）为0.95；而相对危险度为0.95。 95％置信区间（CI）为0.78-1.15； P = 0.59]在治疗后24个月。该结果与他们在挪威同时代的2012年导管导向静脉溶栓试验（CaVenT）的研究相矛盾，该试验是一项较小的随机对照试验，该研究报道CDT治疗的患者中PTS的发生率比单纯抗凝治疗的要低（）。
展开▼
